Pain innovation Target buyers: chronic pain management providers and clinics seeking non-opioid, non-invasive therapies. Leverage NeuraLace’s Axon Therapy and ASNP case reports to position as a leading alternative or adjunct to conventional treatments, highlighting reduced side effects and potential for improved patient outcomes.

Non-invasive focus Sales opportunity with medical facilities prioritizing non-invasive solutions for chronic pain. Emphasize the magnetic peripheral nerve stimulation technology as a safer pain relief option that can expand market share among providers cautious about opioids and invasive procedures.

Early-stage growth Leverage startup characteristics and recent funding history to approach venture-friendly hospitals, academic medical centers, and pilot programs. Position as a high-growth vendor with scalable tech, ready for limited deployments and data collection on outcomes.

Clinical validation Capitalize on conference engagements and published case reports to support ROI narratives. Provide clinicians with compelling evidence of efficacy for chronic low back pain unresponsive to CMM, supporting faster adoption cycles through clinical champions.

Digital readiness Utilize existing tech stack and digital channels to reach target buyers. Propose multi-channel outreach and digital product education, partnering with clinics and distributors via LinkedIn advertising, ecommerce-enabled support, and streamlined onboarding to accelerate procurement.